Coronavirus | Covaxin Phase III trial from November

Grant Boone
October 27, 2020

Israel will begin its first clinical trials of a novel coronavirus vaccine next month, authorities said Sunday (Oct 25), as the country grapples with a second wave of infections. The vaccine produces a robust immune response in elderly people, the group at highest risk.

Japan expects to have the COVID-19 vaccine in the first half of 2021, which will be sufficient for the entire population.

After AstraZeneca announced that an immune response was being produced in both younger and older adults, Adar Poonawalla whose Serum Institute is developing Covidhield in India said " A lot of people were wondering and asking the question, will these early vaccines be effective for the elderly and most vulnerable, here is some preliminary good news".

"The results further build the body of evidence for the safety and immunogenicity of AZD1222", a spokesman said.

Asked if some people could receive a vaccine this year, he told the BBC: "I don't rule that out but that is not my central expectation".

"The programme is progressing well, (but) we're not there yet", Hancock said. With the Astra-Oxford vaccine already under an accelerated review in Europe, it's possible the shot could be approved by European Union or United Kingdom regulators first.

Details of the latest findings are expected to be published shortly in a clinical journal, the Financial Times reported.

More areas in England to move into top tier of COVID restrictions
Greater Manchester, Liverpool City Region, Lancashire and South Yorkshire are now on England's highest alert level Tier Three. The council will receive £1.68million to help with contact tracing and enforcement, and £4.2million for businesses.

The company released similar results back in July, but for healthy adults between the ages of 18 and 55.

Several dozen vaccine candidates are now being tested in clinical trials, ten of which are in the most advanced Phase 3 stage involving tens of thousands of volunteers.

The U.S. Food and Drug Administration authorized the trial to resume Friday, almost two months after a volunteer in a United Kingdom study became ill, and weeks after other regulators elsewhere had cleared tests to resume.

Of them, a total of 19 clinical trials - 17 treatment candidates and two vaccine candidates - are now being conducted, the ministry said.

Cadila Healthcare is planning to hire contract manufacturers for 50-70 million doses of its vaccine, which is an addition to its own capacity of 100 million, Managing Director Sharvil Patel told Bloomberg.

US officials have pushed vaccine developers to work to include a representative number of minorities in their clinical trials.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER